COMP <GO>
CV vs MRK // ALTMAN Z-SCORE & DEBT/EQUITY
CapsoVision Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: CV 3
— MRK 8
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: CV
LAST: $6.83 (-1.58%) • MKT CAP: $369.2M
balance-sheet
26.00
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
balance-sheet
5.19
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CV VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CV | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 52.90% | 74.80% | -21.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.22% | 3.42% | -9.64 | MRK | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.30% | -94.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.10% | -88.10 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 15.30% | 1.30% | +14.00 | CV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 26.00 | 5.19 | +20.81 | CV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.5 | 51.7 | +4.80 | CV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $369.2M | $361.02B | -$360.65B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CV REV | MRK REV | CV GROSS % | MRK GROSS % | CV FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $13.6M | $65.01B | 52.9% | 74.8% | -$23.0M | $12.36B |
| FY 2024 | $11.8M | $64.17B | 54.2% | 76.3% | -$20.2M | $18.10B |
| FY 2023 | — | $60.12B | — | — | — | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CV // BETA —
MRK // BETA 0.92